131I Metaiodobenzylguanidine Therapy of Pheochromocytoma

嗜铬细胞瘤是合成和分泌儿茶酚胺的嗜铬细胞的肿瘤。本项目检测131i -甲氧十二苄基胍（131I-MIBG）放射毒性治疗恶性嗜铬细胞瘤的疗效，特别是检测治疗前“致敏”是否增加了131I-MIBG治疗在减少肿瘤大小、数量和肿瘤负担方面的疗效。中心假设是，在恶性嗜铬细胞瘤患者中，使用131I-MIBG治疗可破坏肿瘤细胞，从而减少肿瘤的大小和数量，减轻肿瘤负担；“增敏”程序增强了131I-MIBG的有效性。这项新方案仍需要FDA的一些澄清，因此，到目前为止还没有患者被纳入这项研究。

Pheochromocytomas are tumors of chromaffin cells that synthesize and secrete catecholamines. This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-metaiodobenzylguanidine (131I-MIBG), and in particular tests whether pre-treatment "sensitization" increases the efficacy of 131I-MIBG treatment in reducing the size and number of tumors and the tumor burden. The central hypothesis is that in patients with malignant pheochromocytoma, treatment with 131I-MIBG destroys tumor cells and thereby decreases the size and number of tumors and the tumor burden; and that the "sensitization" procedures augment the effectiveness of 131I-MIBG. This new protocol still needs some clarifications from the FDA, therefore, no patients have been enrolled into the study so far.